Biotechnology Top Losers: Regulus Therapeutics Inc. (NASDAQ:RGLS), Genetic Technologies Limited (NASDAQ:GENE), NanoString Technologies (NASDAQ:NSTG), MediciNova Inc. (NASDAQ:MNOV), Medgenics (NYSEMKT:MDGN)

Regulus Therapeutics Inc. (NASDAQ:RGLS), announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 (“miR-122”), for the treatment of hepatitis C virus infection (“HCV”). On Monday shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) closed at $15.64. Company’s EPS growth for next 5 years is recorded as 39.60%.

On 28 January, Genetic Technologies Limited (NASDAQ: GENE) reported that up to 6 new breast diagnosis/treatment centres are expected to begin offering BREVAGenplus to their at-risk patients in a systematic broad Genetic Technologies Ltd. (NASDAQ: GENE) fashion in the January to March timeframe, with a growing number of additional new breast and imaging centre customers expected to follow later in calendar year 2015. Genetic Technologies Limited (NASDAQ:GENE) in last trading activity moved down -6.84% to close at $3.68. Company weekly performance is 42.08% while its quarterly performance stands at 67.27%. Genetic Technologies Limited (NASDAQ:GENE) is -69.46% away from its 52 week high.

NanoString Technologies, Inc. (NASDAQ:NSTG), announced that its management is scheduled to present at the 2015 Leerink Global Healthcare Conference in New York. Brad Gray, President and Chief Executive Officer, is scheduled to present on Wednesday, February 11, 2015 at 8:25am ET.On last trading day NanoString Technologies, Inc. (NASDAQ:NSTG) moved down -5.48% to close at $12.77. Its volatility for the week is 5.26% while volatility for the month is 5.46%. NSTG’s sales growth for past 5 years was 81.40% and its EPS growth for past 5 years was 33.60%. NanoString Technologies, Inc. (NASDAQ:NSTG) monthly performance is -2.44%.

On 3 February, MediciNova, Inc., (NASDAQ:MNOV) announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of NASH (nonalcoholic steatohepatitis). MediciNova Inc. (NASDAQ:MNOV) has 0.30% insider ownership while its institutional ownership stands at 9.80%. In last trading activity company’s stock closed at $4.00.

Medgenics, Inc. (NYSEMKT:MDGN) will host a conference call and live audio webcast on Friday, February 13, 2015 at 8:30 a.m. ET to discuss fourth quarter and full year 2014 financial results. On last trading day Medgenics, Inc. (NYSEMKT:MDGN) moved down -5.66% to close at $7.00. Its volatility for the week is 6.81% while volatility for the month is 8.23%. MDGN’s EPS growth for past 5 years was 10.00%. Medgenics, Inc. (NYSEMKT:MDGN) monthly performance is 10.41%.

Leave a Reply

Your email address will not be published.